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Summary
OBJECTIVES: Most urinary tract infections (UTIs) are
treated empirically with antibiotics, making comprehensive
resistance surveillance data essential to guide empiric
regimens. We describe trends in the antibiotic resistance
of urinary Enterobacteriaceae isolates in Switzerland be-
tween 2009 and 2016.
METHODS: We analysed data from routinely collected
Escherichia coli, Klebsiella pneumoniae and Proteus
mirabilis urinary samples from community and hospital
settings in Switzerland. The data were collected by AN-
RESIS, the national laboratory-based antimicrobial resis-
tance surveillance system. Our analyses focused on re-
sistance to antibiotics commonly prescribed for UTIs for
the period 2009–2016. Only the first isolate per patient per
year was included.
RESULTS: 297,200 urinary samples were included in the
analysis, of which 246,656 (83.0%) were E. coli isolates.
Overall, E. coli showed high susceptibility to 3rd/4th-gen-
eration cephalosporins, nitrofurantoin and fosfomycin, with
the annual proportions of resistant isolates <6%, <5% and
<2%, respectively, for all study years. Resistance to flu-
oroquinolones was >14% and increased over time (from
14.5% in 2009 to 19.3% in 2016). Resistance to cotri-
moxazole was >20% for the whole study period. K. pneu-
moniae (n = 32,757; 11.0%) showed low resistance to
cotrimoxazole and quinolones (<11% and <12%, respec-
tively), while for P. mirabilis (n = 17,787; 6.0%) the propor-
tion of resistant isolates was <35% for cotrimoxazole and
<18% for quinolones. Even though quinolone resistance
remained low for both pathogens (<12% for K. pneumo-
niae and <18% for P. mirabilis), it increased significantly
over time. Proportions of isolates resistant to 3rd/4th gener-
ation cephalosporins remained low (<5% for K. pneumoni-
ae and <2% for P. mirabilis), but in the case of K. pneumo-
niae they increased over time.
CONCLUSIONS: Swiss surveillance data confirm that re-
sistance among uropathogenic E. coli isolates to nitrofu-
rantoin and fosfomycin remains low. While resistance to
3rd/4th-generation cephalosporins also remains relatively
low, it has been increasing and needs further surveillance.
As for K. pneumoniae and P. mirabilis, high levels of sus-
ceptibility to 3rd-generation cephalosporins and quinolones
were confirmed, while high prevalences of resistance to
nitrofurantoin and fosfomycin discourage their use as first-
line therapies for these pathogens.
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Introduction
Urinary tract infections (UTIs), particularly uncomplicated
cystitis in women, are a frequent cause of antibiotic use in
the community and hospital settings [1–3]. Enterobacteri-
aceae, primarily Escherichia coli, are the main pathogens,
responsible for >80% of episodes where a pathogen is
identified [4]. Until recently, lower UTIs were commonly
treated with fluoroquinolones, resulting in a rapidly in-
creasing prevalence of quinolone-resistant E. coli in many
countries [5]. In addition, Enterobacteriaceae that produce
extended-spectrum beta-lactamases (ESBL) have become
endemic in many parts of the world, including Switzerland
[6–8]. Recent guidelines (including Swiss guidelines) on
UTI now recommend nitrofurantoin and fosfomycin as
first-line options for lower UTI in women and discourage
the use of quinolones for acute cystitis because of their po-
tential collateral damage in terms of the selection of drug-
resistant organisms [9]. Nitrofurantoin and fosfomycin
continue to have good activity against most E. coli isolates,
including ESBL producers, and have a smaller ecologic
impact than the fluoroquinolones [10–12]. We examined
antibiotic resistance trends and assessed whether an in-
crease in resistance to the newly recommended agents or a
decrease in quinolone resistance had occurred in Switzer-
land between 2009 and 2016.
Methods
Antibiotic resistance data for urinary isolates from adult
patients (>15 years) for E. coli, Klebsiella pneumoniae and
Proteus mirabilis were obtained from the ANRESIS data-
base. ANRESIS (the Swiss Centre for Antibiotic Resis-
tance) is the national surveillance system that collects an-
tibiotic resistance data from routinely collected samples
from a selection of microbiology laboratories. These labo-
ratories are distributed homogeneously across Switzerland
and represent at least 70% of the annual hospitalisation
days and at least 30% of Swiss practitioners [13–15].
For the present analysis we only used data collected by
the 11 laboratories that provided data on at least 200 uri-
nary samples per year for the entire study period (2009 to
2016). Only the first isolate per patient per year was in-
cluded, unless the same patient had multiple isolates from
the same year but with different resistance patterns. Iso-
lates that grew >1 pathogen were also included. Antimicro-
bial susceptibility testing was performed according to the
guidelines of the Clinical and Laboratory Standards Insti-
tute (CLSI) or the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) [16, 17]. Most laborato-
ries switched from CLSI to EUCAST breakpoints between
2011 and 2013 (Enterobacteriaceae CLSI and EUCAST
cut-offs at the time of the switch are reported for selected
antibiotics in table 1). Isolates with intermediate suscepti-
bilities were considered resistant. An isolate with interme-
diate or full resistance to an antibiotic was considered re-
sistant to the antibiotic’s entire class.
Isolates resistant to at least one 3rd/4th-generation
cephalosporin are often used as surrogates for ESBL pro-
ducers [18] (data regarding the confirmation of ESBL pro-
duction was not available, and the data are therefore most
likely an overestimation of ESBL prevalence since other
mechanisms of resistance may cause resistance to 3rd/
4th-generation cephalosporins) [6].
Results were stratified by setting (“inpatients” versus “out-
patients”, i.e. isolates from patients having consulted a
general practitioner (GP) versus isolates from patients in
emergency departments and outpatient clinics within hos-
pitals), age (<65 or ≥65 years) and sex. All data were
analysed using Stata v15 (StataCorp, College Station, TX,
USA). We reported the proportions (%) of antibiotic-resis-
tant isolates in the first and last year of the study period
and analysed the time trends between 2009 and 2016 with
the χ2 test. We also tested differences between the propor-
tions in various subgroups (e.g. inpatients versus outpa-
tients, males versus females) using the z test. A two-sided
p value of <0.05 was considered statistically significant.
Results
The database included 246,656 E. coli (83.0%), 32,757
K. pneumoniae (11.0%) and 17,787 (6.0%) P. mirabilis
urinary isolates from 233,746 patients. The basic charac-
teristics of the study population are described in table 2.
238,403 (80.2%) isolates were from female patients. The
median age was 65 years (interquartile range [IQR] 40-80),
and male patients were older than female patients (mean
age 65.7 years versus 57.2 years, p <0.01).
Most samples were collected in an outpatient setting (GPs
47.6% and outpatient clinics 21.8%). E. coli remained the
most frequently identified pathogen in all years (range
82.2-83.9%) in both community (84.7% in isolates from
outpatient clinics and 85.6% in those from GPs) and hospi-
tal (77.7%) isolates. The key findings are presented in fig-
ures 1–3 and tables 3 and 4.
Escherichia coli
High susceptibility to nitrofurantoin and fosfomycin were
consistently observed, with overall annual proportions of
resistant isolates <5% and <2% respectively, across all set-
Table 1: CLSI and EUCAST minimum inhibitory concentration (MIC) breakpoints for Enterobacteriaceae for selected antibiotics.
Antibiotic CLSI MIC breakpoints (mg/l)* EUCAST MIC breakpoints (mg/l)†
S ≤ R ≥ S ≤ R >
Nitrofurantoin 32 128 64 64
Oral fosfomycin 64 256 32 32
Cotrimoxazole 2 4 2 4
Ciprofloxacin 1 (0.25) 4 (1) 0.5 (0.25) 1 (0.5)
Ceftriaxone 1 4 1 2
Cefepime 8 (2) 32 (16) 1 4
CLSI = Clinical and Laboratory Standards Institute; EUCAST = European Committee on Antimicrobial Susceptibility Testing * Breakpoints refer to the M100 S21 document (Jan-
uary 2011), in brackets the values from the most recent M100 S29 edition (January 2019). † Breakpoints refer to the 2011 document (v 1.3), in brackets the values from the most
recent edition (2019 v 9.0)
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Table 2: Characteristics of the study population.
All
n (%)
E. coli
n (%)
K. pneumoniae
n (%)
P. mirabilis
n (%)
Sex Males 58,797 (19.8) 43,705 (17.7) 8840 (27.0) 11,535 (64.8)
Females 238,403 (80.2) 202,951 (82.3) 23,917 (73.0) 6252 (35.1)
Age (years) <65 (15–64) 142,894 (48.1) 125,703 (51.0) 11,261 (34.4) 5930 (33.3)
≥65 154,309 (51.9) 120,955 (49.0) 21,497 (65.6) 11,857 (66.7)
Setting Inpatients 90,663 (30.5) 70,493 (28.6) 12,980 (39.6) 7190 (40.4)
Outpatients (general practi-
tioners)
141,603 (47.6) 121,189 (49.1) 13,291 (40.6) 7123 (40.0)
Outpatients clinics* 64,937 (21.8) 54,976 (22.3) 6487 (19.8) 3474 (19.5)
* Emergency departments and outpatient clinics within hospitals
Figure 1: Proportion of resistant E. coli isolates from urine samples collected from inpatients and outpatients between 2009 and 2016 in
Switzerland. Data were provided by ANRESIS, the national laboratory-based antimicrobial resistance surveillance system. Vertical black lines
indicate the time period of the switch from CLSI to EUCAST breakpoints.1 Includes outpatient clinics within hospitals
Figure 2: Proportion of resistant K. pneumoniae isolates from urine samples collected from inpatients and outpatients between 2009 and 2016
in Switzerland. Data were provided by ANRESIS, the national laboratory-based antimicrobial resistance surveillance system. Vertical black
lines indicate the time period of the switch from CLSI to EUCAST breakpoints.1 Includes outpatient clinics within hospitals
Figure 3: Proportion ofresistant P. mirabilis isolates from urine samples collected from inpatients and outpatients between 2009 and 2016 in
Switzerland. Data were provided by ANRESIS, the national laboratory-based antimicrobial resistance surveillance system. Vertical black lines
indicate the time period of the switch from CLSI to EUCAST breakpoints. Nitrofurantoin resistance data are not presented since P. mirabilis is
considered to be intrinsically resistant.1 Includes outpatient clinics within hospitals
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Table 3: Number and proportion of E. coli, K. pneumoniae and P. mirabilis resistant isolates in Switzerland, 2009 and 2016.
E. coli K. pneumoniae P. mirabilis
No. resistant isolates / all iso-
lates (%)
p-value No. resistant isolates / all
isolates (%)
p-value No. resistant isolates /
all isolates (%)
p-value
2009 2016 2009 2016 2009 2016
Fosfomycin Switzerland all 140/12,137
(1.1)
432/34,065
(1.3)
<0.001* 493/1214
(40.6)
1035/4460
(23.2)
<0.001* 163/827
(19.7)
426/2282
(18.7)
0.558*
Setting† <0.001‡ 0.894‡ 0.003‡
Inpatients 26/1844
(1.4)
136/9090
(1.5)
0.029* 184/ 325
(56.6)
351/ 1,504
(23.3)
<0.001* 48/197
(24.4)
141/832
(16.9)
0.743*
Outpatients 106/9566
(1.1)
215/18,583
(1.2)
0.003* 283/833
(34.0)
509/2124
(24.0)
<0.001* 109/586
(18.6)
191/1025
(18.6)
0.775*
Outpatient clinics§ 8/727
(1.1)
81/6392
(1.3)
0.023* 26/56
(46.4)
175/832
(21.0)
<0.001* 6/44
(13.6)
94/425
(22.1)
0.002*
Region¶ <0.001‖ <0.001‖ <0.001‖
Sex 0.778‡ <0.001‡ 0.956‡
Female 119/10,380
(1.1)
363/27,941
(1.3)
0.013* 394/946
(41.6)
789/3280
(24.0)
<0.001* 108/555
(19.5)
272/1431
(19.0)
0.526*
Male 21/1757
(1.2)
69/6124
(1.1)
0.001* 99/268
(36.9)
246/1180
(20.8)
<0.001* 55/272
(20.2)
154/851
(18.1)
0.907*
Age ≥65 years 74/5081
(1.5)
260/16,786
(1.5)
0.001* 303/746
(40.6)
717/2947
(24.3)
<0.001* 98/506
(19.4)
305/1530
(19.9)
0.093*
<65 years 66/7056
(0.9)
172/17,279
(1.0)
0.011* 190/468
(40.6)
318/1513
(21.0)
<0.001* 65/321
(20.2)
121/752
(16.1)
0.108*
Nitrofurantoin Switzerland all 997/24,145
(4.1)
297/36,091
(0.8)
<0.001* 1607/2736
(58.7)
2612/3592
(72.7)
<0.001* 1742/1765
(98.7)
2039/2048
(99.6)
0.001*
Setting† <0.001‡ <0.001‡ 0.388‡
Inpatients 310/7697
(4.0)
85/9890
(0.9)
<0.001* 706/1309
(53.9)
731/1076
(67.9)
<0.001* 781/790
(98.9)
712/712
(100.0)
0.001*
Outpatients 526/11,477
(4.6)
148/19,097
(0.8)
<0.001* 629/999
(63.0)
1547/1980
(78.1)
<0.001* 691/705
(98.0)
970/975
(99.5)
0.010*
Outpatient clinics§ 161/4971
(3.2)
64/7104
(0.9)
<0.001* 272/428
(63.5)
334/536
(62.3)
0.009* 270/270
(100.0)
357/361
(98.9)
0.235*
Region¶ <0.001‖ <0.001‖ <0.001‖
Sex <0.001‡ 0.035‡ 0.851‡
Female 798/20,142
(4.0)
223/29,557
(0.7)
<0.001* 1178/2026
(58.1)
1984/2703
(73.4)
<0.001* 1140/1159
(98.4)
1301/1306
(99.6)
<0.001*
Male 199/4003
(5.0)
74/6534
(1.1)
<0.001* 429/710
(60.4)
628/889
(70.6)
<0.001* 602/606
(99.3)
738/742
(99.5)
0.777*
Age ≥65 years 599/11,289
(5.3)
196/17,809
(1.1)
<0.001* 994/1766
(56.3)
1613/2278
(70.8)
<0.001* 1094/1108
(98.7)
1352/1359
(99.5)
0.108*
<65 years 398/12,856
(3.1)
101/18,282
(0.5)
<0.001* 613/970
(63.2)
999/1314
(76.0)
<0.001* 648/657
(98.6)
687/689
(99.7)
0.001*
Quinolones Switzerland all 3622/24,971
(14.5)
7032/
36,342
(19.3)
<0.001* 129/2872
(4.5)
591/5186
(11.4)
<0.001* 225/1904
(11.8)
459/2609
(17.6)
<0.001*
Setting† <0.001‡ 0.971‡ <0.001‡
Inpatients 1432/8090
(17.7)
2052/9990
(20.5)
<0.001* 71/1373
(5.2)
220/1910
(11.5)
<0.001* 108/871
(12.4)
159/1035
(15.4)
0.002*
Outpatients 1497/11,534
(13.0)
3627/
19,097
(19.0)
<0.001* 40/1017
(3.9)
276/2285
(12.1)
<0.001* 79/725
(10.9)
189/1096
(17.2)
<0.001*
Outpatient clinics§ 693/5347
(13.0)
1353/7255
(18.6)
<0.001* 18/482
(3.7)
95/991
(9.6)
<0.001* 38/308
(12.3)
111/478
(23.2)
<0.001*
Region¶ <0.001‖ <0.001‖ <0.001‖
Sex <0.001‡ <0.001‡ <0.001‡
Female 2702/20,786
(13.0)
5222/
29,766
(17.5)
<0.001* 78/2127
(3.7)
363/3794
(9.6)
<0.001* 142/1237
(11.5)
254/1640
(15.5)
<0.001*
Male 920/4185
(22.0)
1810/6576
(27.5)
<0.001* 51/745
(6.8)
228/1392
(16.4)
<0.001* 83/667
(12.4)
205/969
(21.2)
<0.001*
Age ≥65 years 2346/11,766
(19.9)
4117/17,947
(22.9)
<0.001* 84/1858
(4.5)
406/3462
(11.7)
<0.001* 167/1212
(13.8)
360/1766
(20.4)
<0.001*
<65 years 1276/13,205
(9.7)
2915/
18,395
(15.8)
<0.001* 45/1014
(4.4)
185/1724
(10.7)
<0.001* 58/692
(8.4)
99/843
(11.7)
<0.001*
Cotrimoxazole Switzerland all 5704 /24,823
(23.0)
7333/
34,423
(21.3)
<0.001* 310/2864
(10.8)
487/4820
(10.1)
0.001* 671/1889
(35.5)
745/2446
(30.5)
<0.001*
Setting† <0.001‡ <0.001‡ 0.184‡
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tings. Nevertheless, a significant increase over time was
observed for fosfomycin (from 1.1% in 2009 to 1.3% in
2016; p <0.001) while resistance to nitrofurantoin de-
creased (4.1% in 2009 to 0.8% in 2016; p <0.001). Re-
sistance to quinolones increased from 14.5% in 2009 to
19.3% in 2016 (p <0.001). Resistance to cotrimoxazole de-
creased from 23.0% in 2009 to 21.3% in 2016 (p <0.001)
but always remained >20%. E. coli resistant to 3rd/4th-
generation cephalosporins increased in all settings, from
2.9% in 2009 to 5.3% in 2016 (p <0.001).
E. coli K. pneumoniae P. mirabilis
No. resistant isolates / all iso-
lates (%)
p-value No. resistant isolates / all
isolates (%)
p-value No. resistant isolates /
all isolates (%)
p-value
2009 2016 2009 2016 2009 2016
Inpatients 1976/8082
(24.4)
1881/8607
(21.8)
<0.001* 155/1371
(11.3)
178/1617
(11.0)
0.300* 293/870
(33.7)
267/898
(29.7)
0.003*
Outpatients 2463/11,395
(21.6)
3890/
19,054
(20.4)
<0.001* 110/1011
(10.9)
186/2282
(8.1)
<0.001* 278/711
(39.1)
315/1089
(28.9)
<0.001*
Outpatient clinics§ 1265/5346
(23.7)
1562/6762
(23.1)
0.364* 45/482
(9.3)
123/921
(13.4)
0.374* 100/308
(32.5)
163/459
(35.5)
0.869*
Region¶ <0.001‖ <0.001‖ <0.001‖
Sex <0.001‡ <0.001‡ 0.275‡
Female 4684/20,637
(22.7)
5785/
28,241
(20.5)
<0.001* 212/2119
(10.0)
289/3538
(8.2)
<0.001* 434/1222
(35.5)
462/1543
(29.9)
<0.001*
Male 1020/4186
(24.4)
1548/6182
(25.0)
0.542* 98/745
(13.1)
198/1282
(15.4)
0.908* 237/667
(35.5)
283/903
(31.3)
0.001*
Age ≥65 years 2832/11,762
(24.1)
3715/
16,778
(22.1)
<0.001* 177/1856
(9.5)
314/3191
(9.8)
0.092 454/1212
(37.5)
544/1644
(33.1)
<0.001*
<65 years 2872/13,061
(22.0)
3618/
17,645
(20.5)
<0.001* 133/1008
(13.2)
173/1629
(10.6)
0.002 217/677
(32.1)
201/802
(25.1)
<0.001*
3rd/4th-gener-
ation
cephalosporins
Switzerland all 697/23,850
(2.9)
1942/
36,469
(5.3)
<0.001* 79/2732
(2.9)
229/5195
(4.4)
<0.001* 24/1805
(1.3)
24/2618
(0.9)
0.931*
Setting† <0.001‡ <0.001‡ 0.001‡
Inpatients 269/7714
(3.5)
693/10,038
(6.9)
<0.001* 48/1317
(3.6)
93/1913
(4.9)
0.002* 13/826
(1.6)
11/1038
(1.1)
0.736*
Outpatients 276/11,144
(2.5)
777/19,140
(4.1)
<0.001* 24/986
(2.4)
79/2288
(3.4)
0.001* 9/696
(1.3)
10/1099
(0.9)
0.353*
Outpatient clinics§ 152/4992
(3.0)
472/7291
(6.5)
<0.001* 7/429
(1.6)
57/994
(5.7)
<0.001* 2/283
(0.7)
3/ 481
(0.6)
0.916*
Region¶ <0.001‖ <0.001‖ <0.001‖
Sex <0.001‡ <0.001‡ 0.368‡
Female 507/19,860
(2.5)
1338/
29,860
(4.5)
<0.001* 50/2017
(2.5)
120/3798
(3.2)
0.003* 15/1169
(1.3)
16/1646
(1.0)
0.939*
Male 190/3990
(4.8)
604/6609
(9.1)
<0.001* 29/715
(4.1)
109/1397
(7.8)
<0.001* 9/636
(1.4)
8/972
(0.8)
0.989*
Age ≥65 years 385/11,201
(3.4)
1151/18,042
(6.4)
0.679 * 54/1768
(3.0)
161/3469
(4.6)
<0.001* 12/1136
(1.1)
18/1773
(1.0)
0.679*
<65 years 312/12,649
(2.5)
791/18,427
(4.3)
0.612 * 25/964
(2.6)
68/1726
(3.9)
0.017 * 12/669
(1.8)
6/845
(0.7)
0.612*
* Significance level indicating evidence of a linear trend between 2009 and 2016 (χ2 test for trend) † For this analysis (difference between two proportions) outpatient included
general practices, emergency departments and outpatient clinics within hospitals ‡ Significance level indicating evidence of a difference between proportions of resistant isolates
(z test for the difference between two proportions) § Emergency departments and outpatient clinics within hospitals ¶ Regional groups: central-east, central-west, east, Geneva,
northeast, northwest, south, west ‖ Significance of the Pearson’s χ2 test for an association between antibiotic resistance and region
Table 4: Resistance of E. coli isolates in 2016 according to age group and setting.
Quinolone resistant
n (%)
Cotrimoxazole resistant
n (%)
3rd/4th-generation
cephalosporin resistant
n (%)
Nitrofurantoin resistant
n (%)
Fosfomycin resistant
n (%)
Patients ≥65 years 4117/17,947
(22.9)
3715/16,778
(22.1)
1151/18,042
(6.4)
196/17,809
(1.1)
260/16,786
(1.5)
Patients <65 years 2915/18,395
(15.8)
3618/17,645
(20.5)
791/18,427
(4.3)
101/18,282
(0.5)
172/17,279
(1.0)
Inpatients 2052/9990
(20.5)
1881/8607
(21.8)
693/10,038
(6.9)
85/9890
(0.9)
136/9090
(1.5)
Outpatients 3627/19,097
(19.0)
3890/19,054
(20.4)
777/19,140
(4.1)
148/19,097
(0.8)
215/18,583
(1.2)
Outpatient clinics* 1353/7255 (18.6) 1562/6762
(23.1)
472/729
(6.5)
64/7104
(0.9)
81/6392
(1.3)
* Emergency departments and outpatient clinics within hospitals
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In 2016, proportions of resistant isolates were higher
among men than women for all antibiotics investigated.
Fosfomycin was the only exception (27.5% versus 17.5%
for quinolones, 25.0% versus 20.5% for cotrimoxazole,
9.1% versus 4.5% for 3rd/4th generation cephalosporins,
1.1% versus 0.7% for nitrofurantoin). Isolates from pa-
tients aged ≥65 years and from inpatients were more resis-
tant for all antibiotic classes investigated (table 4).
Klebsiella pneumoniae
Overall, cotrimoxazole and quinolone resistance remained
low, ranging from 10–11% and 4–11% of all K. pneu-
moniae isolates respectively, although the prevalence of
quinolone-resistant isolates more than doubled from 2009
to 2016 (4.5% to 11.4%, p <0.001). The proportions of 3rd/
4th-generation cephalosporin-resistant isolates increased
overall between 2009 and 2016 (2.9% to 4.4%, p <0.001)
but remained low (<5%), with 2016 resistance prevalences
of 3.4% and 4.9% in outpatient and hospital isolates, re-
spectively (p <0.001). Resistance to fosfomycin and nitro-
furantoin remained high (>20% and >58% of all isolates
respectively) in samples from both hospitals and the com-
munity. Fosfomycin resistance decreased after 2011, how-
ever, from 40.6% to 23.2%.
Proteus mirabilis
In P. mirabilis isolates, the highest prevalence of resistance
was to cotrimoxazole (>30%), while quinolone and fos-
fomycin resistance remained below 20% throughout the
study period. For quinolones, however, resistance in-
creased from 11.8% in 2009 to 17.6% in 2016 (p <0.001).
Cotrimoxazole resistance decreased over time from 35.5%
in 2009 to 30.5% in 2016 (p <0.001). Resistance to 3rd/
4th-generation cephalosporins remained low over the
study period (1.3% in 2009 to 0.9% in 2016) and the
changes in the proportions of resistant isolates were <0.5%
per year in all categories.
Discussion
This retrospective study describes resistance patterns for a
large number of urinary samples collected from inpatients
and outpatients across Switzerland from 2009 to 2016,
with a focus on those antibiotic classes commonly used to
treat UTI. Although many studies have already described
increasing resistance rates in urinary isolates, Swiss data
are limited either to single centre studies or to studies fo-
cusing on resistance to single antibiotic classes [19]. More-
over, to the best of our knowledge, no data on Swiss sam-
ples collected after 2011 have been published. This reflects
a lack of information concerning the impact of the most
recent IDSA/ESCMID (2010) [9] and Swiss (2014) [20]
guidelines, which recommend antibiotics with high effi-
cacy but “minimal resistance and propensity for collater-
al damage”, such as nitrofurantoin and fosfomycin, for un-
complicated cystitis, reserving quinolones for upper UTI.
Moreover, while cotrimoxazole is discouraged by IDSA/
ESCMID guidelines in settings where resistance preva-
lence exceeds 20% (without stating a clear rationale for
this cut-off), it is mentioned together with fosfomycin and
nitrofurantoin as a first-choice option in the Swiss guide-
lines.
In this study we were able to analyse data on resistance to
the more frequently prescribed antibiotics for UTI provid-
ed by a large national surveillance program. The most im-
portant finding of this study was the low resistance (<5%)
of E. coli isolates to both nitrofurantoin and fosfomycin
during the whole study period. Interestingly, resistance to
nitrofurantoin showed a statistically significant decrease
over time for E. coli isolates, from 4.1% in 2009 to 0.8%
in 2016, although this was likely due to the switch from
the CLSI to the EUCAST breakpoints. Resistance to fos-
fomycin increased slightly from 1.1% in 2009 to 1.3% in
2016.
This may be explained in part by a higher uptake of fos-
fomycin by GPs. In fact, in Switzerland between 2013 and
2017 (so going beyond the study period), fosfomycin use
in the outpatient setting went up from 0.03 to 0.04 defined
daily doses (DDD) per 1000 inhabitants per day, while ni-
trofurantoin use went down from 0.23 to 0.20 DDD per
1000 inhabitants per day (unpublished data). This is de-
spite a recent study proving that nitrofurantoin is superi-
or to fosfomycin for both clinical and bacteriological re-
sponse in women treated for uncomplicated UTI [4].
Low proportions of isolates resistant to nitrofurantoin and
fosfomycin were confirmed in samples from both inpatient
and outpatient settings and in all patient age and sex cate-
gories. For nitrofurantoin, our results were similar to those
previously reported in a study investigating resistance
trends in urinary isolates collected at the University Hospi-
tal of Basel, Switzerland until 2007 [5]. On the other hand,
even though the use of quinolones has been discouraged
for the treatment of uncomplicated lower UTI in inter-
national guidelines since 2010 (no Swiss guidelines were
available before 2014), E. coli resistance to quinolones in-
creased over time and reached 19.3% in 2016. This in-
crease was statistically significant and observed for both
inpatient and outpatient isolates. Moreover, it reached
22.9% in patients aged >65 years.
E. coli resistance to 3rd- and 4th-generation
cephalosporins increased over the study period, in line
with data previously published in Switzerland on urinary
and bloodstream infections [7]. Similarly, we observed the
highest incidence and yearly increase in the age group of
over 65 years and in males.
Interestingly, we described similar proportions of resistant
isolates and increases over time between the samples col-
lected at hospitals and those from outpatient clinics,
whereas previously in Switzerland a statistically signif-
icantly higher increase was observed in inpatients, con-
firming the concerns over the risk of community-acquired
resistance to 3rd-generation cephalosporins and its impli-
cations for the empirical treatment of severe infections and
infection control, even in a Swiss context [18].
For cotrimoxazole we observed a slight decrease in the
proportion of resistant E. coli isolates from 2009 to 2016,
from 23% to 21.3%. This probably reflects decreased use
of cotrimoxazole because of concerns about the propor-
tions of resistant isolates being >20% (mentioned – albeit
somewhat arbitrarily – as the cut-off for recommending
against using cotrimoxazole empirically for UTI) [9]. It
is interesting to note that before 2009 resistance to cotri-
moxazole probably increased, as reported in a single-cen-
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tre Swiss study that described an increase in cotrimoxazole
resistance between 1997 and 2007 [5, 18].
K. pneumoniae and P. mirabilis accounted for less than
20% of all isolates and both had high proportions of iso-
lates resistant to nitrofurantoin and fosfomycin, making
them suboptimal options for treating infections caused by
these pathogens. Third-generation cephalosporins and
quinolones retained high intrinsic activity (>85–90% sus-
ceptibility in both pathogens and for both drugs).
The main strength of this study is that it is based on a
large database of urinary samples from both the hospital
and community settings (even though we acknowledge that
the study population only covers 70% of annual hospitali-
sation days and 30% of Swiss practitioners). However, we
also acknowledge its limitations. Firstly, we do not have
clinical information linked to the isolates (including pre-
vious antibiotic use and the fact that we could not estab-
lish if these were asymptomatic bacteriuria, complicated
or uncomplicated UTI) and so it is likely that, especial-
ly in the outpatient setting, the samples that were sent for
testing were those of patients with recurrent infections or
treatment failure. This could lead to a possible overesti-
mation of the real incidence of resistance [19]. Secondly,
most laboratories in Switzerland transitioned from CLSI
to EUCAST, so changes in the proportion of resistant iso-
lates may be in part the consequence of a change in the
cut-offs used to distinguish between susceptible and resis-
tant isolates (even though, as shown in Table 1, in all cas-
es where the cut-off was changed, the minimum inhibito-
ry concentration was lowered even though the proportion
of resistant isolates increased or decreased, depending on
the pathogen). This aspect likely explains the important in-
crease in the susceptibility of K. pneumoniae isolates to
fosfomycin between 2009 and 2016. Furthermore, we do
not have complete information on the trends of antibiotic
use for UTI in Switzerland between 2009 and 2016, mak-
ing it impossible to draw conclusions about the possible
impact of the most recent guidelines on the described pro-
portions of antibiotic-resistant isolates. This represents an
important limitation, since it has been proven, for example,
that antibiotic use for various types of infections (includ-
ing UTIs) is associated with the emergence and selection
of resistance at the individual level, with consequent pos-
sible implications on the ecological level (i.e. community,
regional and country levels) [21, 22].
Even though Switzerland has a relatively low antibiotic
consumption in both inpatient and outpatient settings com-
pared to other European countries (10.7 DDD/1000 inhab-
itants in the outpatient setting in 2017 versus 21.8 DDD/
1000 inhabitants in the European Union (EU) in the same
year, and 60 DDD/100 bed-days in Swiss hospitals), some
antibiotic classes (such as quinolones) are probably
overused and we believe the findings of this study high-
light the potential to reduce inappropriate antibiotic use
and to standardise UTI treatment in Switzerland.
For example, in light of these findings, the use of cotri-
moxazole as a first-line agent for lower UTI (even though
overall resistance for E. coli exceeds 20%) must be recon-
sidered (and it is indeed suggested as an option in the 2014
Swiss guidelines). As mentioned in the IDSA guidelines
[9], the threshold of 20% as the resistance prevalence at
which the agent is no longer recommended is based on
expert opinion derived from clinical, in vitro and mathe-
matical modelling studies. It is important to remember that
cystitis is mostly a self-limited condition and 25–42% of
women may resolve spontaneously [23], that surveillance
data tend to overestimate resistance (because cultures are
often requested for more severe or unresponsive cases) and
that urinary concentrations of certain antibiotics (includ-
ing cotrimoxazole) may be higher than those achieved in
the serum with equivalent doses (and susceptibility break-
points are based on achievable serum and not urine con-
centrations) [24]. All these arguments support the attitude
that cotrimoxazole can be reconsidered.
To conclude we observed an increase over time in re-
sistance in urinary isolates for antibiotic classes such as
quinolones (for all three described pathogens, highlighting
the need for antibiotic stewardship) and 3rd- and 4th-gen-
eration cephalosporins (for E. coli and K. pneumoniae). We
confirmed the high levels of susceptibility to nitrofuran-
toin and fosfomycin among E. coli isolates (but not among
K. pneumoniae or P. mirabilis isolates, making them good
options for the empiric treatment of uncomplicated lower
UTI, since E. coli is by far the most common causative
pathogen). The proportion of cotrimoxazole-resistant iso-
lates decreased for all isolates but remained >20% for E.
coli and P. mirabilis in all settings. Although we did not
comment in our discussion on the impact of antibiotic use
in animals on the selection for bacteria resistant to the an-
tibiotics used in humans, we acknowledge that in order to
combat antimicrobial resistance in gram-negative bacteria,
a holistic and multisectoral approach (referred to as One
Health) is important.
The preliminary results of this study were presented as a
poster presentation (P11529) at the 26th European Con-
gress of Clinical Microbiology and Infectious Diseases
(ECCMID); 9–12 April 2016; Amsterdam, The Nether-
lands.
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